Cannabis is the most commonly used illicit drug worldwide. With debate surrounding the legalization and control of use, investigating its health risks has become a pressing area of research. One established association is that between cannabis use and schizophrenia, a debilitating psychiatric disorder affecting ~1% of the population over their lifetime. Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use. In a sample of 2082 healthy individuals, we show an association between an individual’s burden of schizophrenia risk alleles and use of cannabis. This was significant both for comparing those who have ever versus never used cannabis (P=2.6 × 10−4), and for quantity of use within users (P=3.0 × 10−3). Although directly predicting only a small amount of the variance in cannabis use, these findings suggest that part of the association between schizophrenia and cannabis is due to a shared genetic aetiology. This form of gene–environment correlation is an important consideration when calculating the impact of environmental risk factors, including cannabis use.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
A network approach to relationships between cannabis use characteristics and psychopathology in the general population
Scientific Reports Open Access 03 May 2022
npj Schizophrenia Open Access 12 May 2021
Translational Psychiatry Open Access 13 April 2021
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
United Nations Office on Drugs and Crime. World Drug Report 2013. United Nations: New York, NY, USA, 2013.
Green B, Young R, Kavanagh D . Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187: 306–313.
McGuire PK, Jones P, Harvey I, Bebbington P, Toone B, Lewis S et al. Cannabis and acute psychosis. Schizophr Res 1994; 13: 161–167.
Thornicroft G . Cannabis and psychosis. Is there epidemiological evidence for an association?. Br J Psychiatry 1990; 157: 25–33.
Tien AY, Anthony JC . Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 1990; 178: 473–480.
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572.
Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 39: 1607–1616.
van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H . Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319–327.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–2518.
Arseneault L, Cannon M, Witton J, Murray RM . Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110–117.
McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67: 440–447.
Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G . Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199.
Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330: 11.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–328.
Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE . Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212–1213.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–2196.
Addington J, Duchak V . Reasons for substance use in schizophrenia. Acta Psychiatr Scand 1997; 96: 329–333.
Spencer C, Castle D, Michie PT . Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002; 28: 233–247.
Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC . Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100: 612–618.
Fergusson DM, Horwood LJ, Ridder EM . Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005; 100: 354–366.
Compton MT, Furman AC, Kaslow NJ . Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71: 61–64.
Peralta V, Cuesta MJ . Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85: 127–130.
Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ . Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224–230.
Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM . Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008; 34: 1111–1121.
Sullivan PF, Kendler KS, Neale MC . Schizophrenia as a complex trait—Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187–1192.
Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969–976.
Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45: 1150–1159.
Kendler KS, Schmitt E, Aggen SH, Prescott CA . Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry 2008; 65: 674–682.
Agrawal A, Lynskey MT . The genetic epidemiology of cannabis use, abuse and dependence. Addiction 2006; 101: 801–812.
Verweij KJ, Zietsch BP, Lynskey MT, Medland SE, Neale MC, Martin NG et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 2010; 105: 417–430.
Verweij KJ, Vinkhuyzen AA, Benyamin B, Lynskey MT, Quaye L, Agrawal A et al. The genetic aetiology of cannabis use initiation: a meta-analysis of genome-wide association studies and a SNP-based heritability estimation. Addict Biol 2013; 18: 846–850.
Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748–752.
Bucholz KK, Heath AC, Madden PA . Transitions in drinking in adolescent females: evidence from the Missouri adolescent female twin study. Alcohol Clin Exp Res 2000; 24: 914–923.
Knopik VS, Heath AC, Madden PA, Bucholz KK, Slutske WS, Nelson EC et al. Genetic effects on alcohol dependence risk: re-evaluating the importance of psychiatric and other heritable risk factors. Psychol Med 2004; 34: 1519–1530.
Heath AC, Whitfield JB, Martin NG, Pergadia ML, Goate AM, Lind PA et al. A quantitative-trait genome-wide association study of alcoholism risk in the community: findings and implications. Biol Psychiatry 2011; 70: 513–518.
Medland SE, Nyholt DR, Painter JN, McEvoy BP, McRae AF, Zhu G et al. Common variants in the trichohyalin gene are associated with straight hair in Europeans. Am J Hum Genet 2009; 85: 750–755.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
StataCorp. Stata Statistical Software: Release 12. StataCorp LP: College Station, TX, USA, 2011.
Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381: 1371–1379.
Foti DJ, Kotov R, Guey LT, Bromet EJ . Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010; 167: 987–993.
Power RA, Wingenbach T, Cohen-Woods S, Uher R, Ng MY, Butler AW et al. Estimating the heritability of reporting stressful life events captured by common genetic variants. Psychol Med 2012; 43: 1965–1971.
Whitfield JB, Zhu G, Heath AC, Martin NG . Choice of residential location: chance, family influences, or genes? Twin Res Hum Genet 2005; 8: 22–26.
Winter T, Kaprio J, Viken RJ, Karvonen S, Rose RJ . Individual differences in adolescent religiosity in Finland: familial effects are modified by sex and region of residence. Twin Res 1999; 2: 108–114.
Hickman M, Vickerman P, Macleod J, Lewis G, Zammit S, Kirkbride J et al. If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction 2009; 104: 1856–1861.
Robert Power was funded by the Medical Research Council and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This work was supported by National Institutes of Health Grants AA07535, AA0758O, AA07728, AA10249, AA13320, AA13321, AA14041, AA11998, AA17688, DA012854, DA018267, DA018660, DA23668 and DA019951; by Grants from the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498, 6136022, 628911 and 1047956); by Grants from the Australian Research Council (A7960034, A79906588, A79801419, DP0770096, DP0212016 and DP0343921); and by the 5th Framework Programme (FP-5) GenomEUtwin Project (QLG2-CT-2002-01254). This research was further supported by the Centre for Research Excellence on Suicide Prevention (CRESP—Australia). KJHV is supported by the Netherlands Organization for Health Research and Development, ZonMW 31160212. We thank Richard Parker, Soad Hancock, Judith Moir, Sally Rodda, Pieta-Maree Shertock, Heather Park, Jill Wood, Pam Barton, Fran Husband, Adele Somerville, Ann Eldridge, Marlene Grace, Kerrie McAloney, Lisa Bowdler, Alexandre Todorov, Steven Crooks, David Smyth, Harry Beeby and Daniel Park. Finally, we thank the twins and their families for their participation.
The authors declare no conflict of interest.
About this article
Cite this article
Power, R., Verweij, K., Zuhair, M. et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry 19, 1201–1204 (2014). https://doi.org/10.1038/mp.2014.51
This article is cited by
The one-month prevalence and correlates of psychotic-like experiences in the general adult population in Nigeria
Current Psychology (2023)
A network approach to relationships between cannabis use characteristics and psychopathology in the general population
Scientific Reports (2022)
npj Schizophrenia (2021)
Translational Psychiatry (2021)
Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort
Translational Psychiatry (2020)